Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Gilead Sciences (NASDAQ:GILD) had its price objective lifted by equities researchers at Wells Fargo & Company from $120.00 to $140.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price suggests a potential upside of 20.65% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. Piper Sandler upped their price objective on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. Truist Financial boosted their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research note on Friday, November 8th. Wolfe Research started coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target for the company. Finally, Daiwa America upgraded Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $104.24.

Gilead Sciences Stock Up 0.5 %

Shares of Gilead Sciences stock opened at $116.04 on Wednesday. The firm’s 50 day moving average price is $99.15 and its 200-day moving average price is $91.09. The company has a market cap of $144.62 billion, a P/E ratio of 313.62, a PEG ratio of 0.71 and a beta of 0.21. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 52-week low of $62.07 and a 52-week high of $117.39.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, sell-side analysts predict that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 8,500 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $91.96, for a total value of $781,660.00. Following the completion of the sale, the chief financial officer now directly owns 132,373 shares of the company’s stock, valued at $12,173,021.08. This trade represents a 6.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 293,356 shares of company stock worth $29,166,240 in the last quarter. Company insiders own 0.16% of the company’s stock.

Institutional Trading of Gilead Sciences

A number of institutional investors have recently added to or reduced their stakes in the stock. Swedbank AB boosted its position in shares of Gilead Sciences by 10.2% in the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock worth $171,672,000 after buying an additional 189,622 shares in the last quarter. Crestwood Advisors Group LLC boosted its stake in shares of Gilead Sciences by 10.1% during the third quarter. Crestwood Advisors Group LLC now owns 12,176 shares of the biopharmaceutical company’s stock valued at $1,021,000 after acquiring an additional 1,116 shares during the last quarter. Avidian Wealth Enterprises LLC raised its holdings in Gilead Sciences by 3.7% in the 3rd quarter. Avidian Wealth Enterprises LLC now owns 8,612 shares of the biopharmaceutical company’s stock valued at $722,000 after acquiring an additional 310 shares during the last quarter. Catalina Capital Group LLC purchased a new position in shares of Gilead Sciences during the 3rd quarter worth about $323,000. Finally, Radnor Capital Management LLC acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth $229,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.